Recent Updates
Recently added Catalysts
KURA Positive Sentiment

Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place

Friday, December 1, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the importance of internal manufacturing and oversight by Contract Development and Manufacturing Organizations (CDMOs) in the biopharma sector. It highlights the ongoing supply chain shortages expected next year and suggests that collaboration with government regulators can help mitigate these issues. Additionally, it notes that some companies have turned shortages into opportunities.
Price reaction · baseline $9.67 (2023-11-30 close) · hit pre-market · clean, no other KURA news in the window
day 0 close · peak
+3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Emphasis on innovative product types and therapeutic approaches.
  • Collaboration with regulators can facilitate smoother operations.
  • Opportunities arise from addressing supply chain shortages.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic

Full Press Release Details

Magazine Article | December 1, 2023
By Ben Comer , Chief Editor, Life Science Leader
With the enthusiasm surrounding innovative product types and therapeutic approaches — and the corresponding rush to bring these new products to market — company leaders should double down on internal manufacturing and CDMO oversight to prevent unanticipated delays. Supply chain shortages are likely to continue next year, but biopharma leaders suggest that collaboration with government regulators can help grease the skids; in other scenarios, some of which are described below, operations executives have been able to turn other company’s shortages into their own opportunities.

Get unlimited access to:

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today .

Newsletter Signup

Frequently Asked Questions

What is the focus of the article?

The article focuses on biopharma manufacturing and supply chain challenges.

How can biopharma companies address supply chain shortages?

Companies can collaborate with government regulators to mitigate supply chain shortages.

What role do CDMOs play in biopharma?

CDMOs provide oversight and support in the manufacturing process for biopharma products.

What opportunities arise from supply chain issues?

Some companies have turned supply chain shortages into opportunities for growth.

ShareAdd on Google
Tags: KURA Viatris Investor Conferences Healthcare biopharma manufacturing supply chain CDMO regulators
Last updated: Dec 1, 2023

Biotech snapshot

Cash runway
$519M liquidity · $21M/mo burn
~25 mo
Low dilution risk
Lead asset
TipifarnibPhase 2
Leukemia, Myelomonocytic, Chronic →

Catalyst track record

+116%
best trade around KURA's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for KURA.

See every catalyst's timing & PoA →